Antibioprophylaxis in surgery and interventional medicine (adult patients). Update 2017.


Journal

Anaesthesia, critical care & pain medicine
ISSN: 2352-5568
Titre abrégé: Anaesth Crit Care Pain Med
Pays: France
ID NLM: 101652401

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 6 3 2019
medline: 26 9 2020
entrez: 6 3 2019
Statut: ppublish

Résumé

Infection is a risk for any intervention. In surgery, for example, pathogenic bacteria are found in more than 90% of operative wounds during closure. This exists whatever the surgical technique and whatever the environment (the laminar flow does not entirely eliminate this risk). These bacteria are few in number but can proliferate. They find in the operative wound a favourable environment (haematoma, ischaemia, modification of oxido-reduction potential...) and the intervention induces anomalies of the immune defences. In the case of the installation of foreign material, the risk is increased. The objective of antibiotic prophylaxis (ABP) is to prevent bacterial growth in order to reduce the risk of infection at the site of the intervention. The preoperative consultation represents a privileged moment to decide on the prescription of a ABP. It is possible to define the type of intervention planned, the associated risk of infection (and therefore the necessity or not of ABP), the time of prescription before surgery and any allergic antecedents which may modify the choice of the selected antibiotic molecule.

Identifiants

pubmed: 30836191
pii: S2352-5568(19)30085-2
doi: 10.1016/j.accpm.2019.02.017
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Practice Guideline Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

549-562

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

C Martin (C)

Anaesthesia and intensive Care, North university hospital, 13015 Marseille, France.

C Auboyer (C)

Anaesthesia and intensive care, hôpital Nord, 42055 Saint-Étienne, France.

M Boisson (M)

Anaesthesia and intensive care, CHU La Milétrie, 86021 Poitiers, France.

H Dupont (H)

Anaesthesia and intensive care, CHU Amiens, Picardie, 80054 Amiens, France.

R Gauzit (R)

Anaesthesia and intensive care, Hôtel-Dieu, 75181 Paris, France.

M Kitzis (M)

Vascular surgery, hôpital de Vanves, 92170 Vanves, France.

M Leone (M)

Anaesthesia and intensive care, hôpital Nord, 13015 Marseille, France. Electronic address: Marc.LEONE@ap-hm.fr.

A Lepape (A)

Anaesthesia and intensive care, CHU Lyon Sud, 69495 Lyon, France.

O Mimoz (O)

Anaesthesia and intensive care, CHU La Milétrie, 86021 Poitiers, France.

P Montravers (P)

Anaesthesia and intensive care, CHU Bichat-Claude Bernard, 75877 Paris, France.

J L Pourriat (JL)

Anaesthesia and intensive care, Hôtel-Dieu, 75181 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH